[ 18 F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma.
Laura Lavinia TravainiFrancesca BottaEnrico DerenziniGiuliana Lo PrestiMahila Esmeralda FerrariLighea Simona Airò FarullaTommaso RadiceSaveria MazzaraCorrado TarellaStefano PileriSara RaimondiFrancesco CeciPublished in: Hematological oncology (2023)
To evaluate the association between radiomic features (RFs) extracted from 18 F-FDG PET/CT ( 18 F-FDG-PET) with progression-free survival (PFS) and overall survival (OS) in diffuse large-B-cell lymphoma (DLBCL) patients eligible to first-line chemotherapy. DLBCL patients who underwent 18 F-FDG-PET prior to first-line chemotherapy were retrospectively analyzed. RFs were extracted from the lesion showing the highest uptake. A radiomic score to predict PFS and OS was obtained by multivariable Elastic Net Cox model. Radiomic univariate model, clinical and combined clinical-radiomic multivariable models to predict PFS and OS were obtained. 112 patients were analyzed. Median follow-up was 34.7 months (Inter-Quartile Range (IQR) 11.3-66.3 months) for PFS and 41.1 (IQR 18.4-68.9) for OS. Radiomic score resulted associated with PFS and OS (p < 0.001), outperforming conventional PET parameters. C-index (95% CI) for PFS prediction were 0.67 (0.58-0.76), 0.81 (0.75-0.88) and 0.84 (0.77-0.91) for clinical, radiomic and combined clinical-radiomic model, respectively. C-index for OS were 0.77 (0.66-0.89), 0.84 (0.76-0.91) and 0.90 (0.81-0.98). In the Kaplan-Meier analysis (low-IPI vs. high-IPI), the radiomic score was significant predictor of PFS (p < 0.001). The radiomic score was an independent prognostic biomarker of survival in DLBCL patients. The extraction of RFs from baseline 18 F-FDG-PET might be proposed in DLBCL to stratify high-risk versus low-risk patients of relapse after first-line therapy, especially in low-IPI patients.
Keyphrases
- diffuse large b cell lymphoma
- end stage renal disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- pet ct
- chronic kidney disease
- prognostic factors
- positron emission tomography
- squamous cell carcinoma
- pet imaging
- computed tomography
- epstein barr virus
- radiation therapy
- locally advanced
- replacement therapy